RxDoctor Payments Data

Jorge Perez de Armas, MD

Hematology & Oncology · Fort Myers, FLNPI 1427261726

Payments from drug & device makers

$1,655in general payments, 2019–2025

Across 81 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$251
  • Genentech USA, Inc.$225
  • Amgen$173
  • Johnson & Johnson$144
  • AstraZeneca$143
  • Merck$133
  • plus $585 from 16 others

What the payments were for

  • Food & beverage$1,655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,655 in reported general payments places this provider in the 25th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$35,106
Medicare patients
131
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate12$213,983
IbrancePalbociclib11$175,251
Lenalidomide11$146,509
EliquisApixaban118$80,943
XtandiEnzalutamide11$64,957
Imatinib Mesylate14$14,554
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$1,220
Anastrozole77$840
Morphine Sulfate ErMorphine Sulfate16$746
Oxycodone Hcl32$685
Hydroxyurea18$505
Acyclovir44$431
Tamoxifen Citrate19$389
Potassium Chloride38$387
Gabapentin23$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$38$256,194129 claims
AstraZenecaCalquence$143$213,98312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →